C. elegans as a powerful model for studying prodromal PD
While most neurodegenerative disease models focus on late-stage pathology19, studying early disease onset remains technically challenging. Traditional mammalian models, like mice, rats or primates, are constrained by long life cycles and high costs. The microscopic nematode C. elegans overcomes these limitations with its 3-week lifespan, 3-day reproductive cycle, and genetic tractability - making it an ideal system for efficient, large-scale studies of neurodegeneration6.
The C. elegans RAC1/CED-10 mutant provides three key advantages for studying early PD pathogenesis. First, its precise temporal resolution allows neurodegenerative events to be tracked across well-defined developmental stages6. Second, the model offers exceptional experimental versatility through genetic tractability, low maintenance requirements, and high-throughput compatibility6,7. Third, because C. elegans lacks an endogenous α-synuclein homolog, including in the RAC-1/CED-10 model, it provides a valuable advantage. Researchers can examine pre-clinical PD mechanisms without α-synuclein interference, which marks more advanced stages6 . This positions the model as an excellent tool for studying initial pathogenic events and for later integration of α-synuclein expression to investigate advanced pathogenesis. Finally, the evolutionary conservation of CED-10's homology with human RAC1 ensures direct translational relevance10,20.
The C. elegans model described here is well-suited for pharmacological assays17,21. Because RAC-1/CED-10 mutants exhibit developmental delay, blinding is not possible at the initial step, as their identity cannot be concealed relative to the wild type. For pharmacological screenings, however, bias can be minimized by adopting a double-blind design in which the experimenter collecting the data and the person analyzing it remain unaware of all experimental variables.
Constipation affects nearly all PD patients during the prodromal phase, often preceding motor symptoms5. C. elegans offers unique advantages for studying this early gastrointestinal dysfunction. Unlike mammalian models requiring invasive interventions, the nematode's transparency and simplicity enable non-invasive, real-time observation of its highly stereotyped defecation motor program-a feature critical for quantifying gut motility defects. The short life cycle and precise rhythmicity of C. elegans defecation enable rapid and reproducible analysis of functional impairments. In RAC1/CED-10 mutants, deviations in defecation timing mirror constipation-like phenotypes observed in prodromal PD6. These findings provide a foundational framework for later validation in complex mammals (e.g., mice, primates) while directly linking RAC1 signaling to enteric dysfunction.
Beyond its mechanistic relevance, the RAC1/CED-10 model also offers translational utility. The defecation assay is simple, reproducible, and scalable, making it suitable for early-stage drug screening. Compounds that normalize cycle timing or regularity can be rapidly prioritized for testing in mammalian models, providing a cost-effective filter for therapeutic candidates. Because gastrointestinal dysfunction is common across several neurodegenerative conditions4, this assay may also be applied beyond PD, serving as both a discovery tool and a translational bridge to preclinical research.
Critical steps in the protocol
We present a refined methodology to study intestinal dysmotility in RAC1/CED-10 mutants, a key non-motor phenotype relevant to prodromal PD. While based on established defecation assays18,22, this protocol addresses unique challenges posed by RAC1/CED-10 mutants to ensure robust and reproducible results.
The key adaptations for RAC1/CED-10 mutants are as follows:
Synchronization adjustments: RAC1/CED-10 mutants exhibit reduced fecundity compared to wild-type strains (personal observation). To compensate for the lower progeny yield, apply the following adjustments during synchronization: Plate chunk method - use a larger inoculum, approximately 2x the volume used for wild-type strains, to account for increased developmental variability. Gravid adult method - Transfer 15-20 adults (versus standard 10) to ensure a sufficient number of embryos for subsequent experiments.
Bleach sensitivity: Embryos from RAC1/CED-10 mutants exhibit increased sensitivity to hypochlorite treatment. To minimize damage, reduce bleach exposure time by 20%-30% compared to wild-type protocols and verify embryo integrity microscopically after treatment.
Developmental delay considerations: RAC1/CED-10 mutants mature more slowly than wild-type worms10. To achieve proper synchronization for recordings, begin video analyses with wild-type worms to establish a temporal reference and record mutants at matched morphological stages (e.g., vulval morphology) rather than by chronological age.
Workflow rationale: Conducting initial experiments with wild-type C. elegans controls for environmental variability and provides a reference for normal defecation rhythms. Due to developmental delays in RAC1/CED-10-10 mutants, recording schedules should be adapted to prioritize stage-matched (rather than strictly age-matched) comparisons.
Strain-specific timing considerations: Developmental delays in mutants require flexible experimental scheduling, with an emphasis on matching developmental stages across genotypes instead of relying solely on chronological age.
Limitations of the nematode model
While C. elegans lacks the anatomical complexity and pathway redundancy of mammalian systems-a limitation for some translational studies-its simplicity is advantageous for examining discrete biological functions. Focusing on intestinal motility leverages this strength, as the nematode's streamlined physiology allows for the precise analysis of specific functional parameters. Although complementary mammalian studies are necessary for therapeutic validation, C. elegans offers an exceptional platform for the mechanistic investigation of conserved biological processes21,23.
Our model also lacks endogenous α-synuclein, which is beneficial for studying early, preclinical PD (Parkinson's disease), a stage when constipation may emerge as a prodromal symptom3. The defecation cycle length provides an objective, high-throughput measure, but it reflects only one aspect of gastrointestinal dysfunction and is not disease-specific.
While this assay does not capture progressive α-synuclein aggregation, complex neurodegeneration, or age-related systemic pathology seen in human PD5, we observe altered dopaminergic and GABAergic function and disrupted Rac1 signaling6, highlighting the mechanistic relevance of this model. Therefore, it remains valuable for dissecting early PD-related neuro-gastrointestinal mechanisms and conserved pathways.